This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

59/100

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

The pTau217/Aβ42 ratio demonstrated the highest diagnostic accuracy, with an AUC of 0.927 (0.900-0.954). Interpretation The pTau217/Aβ42 ratio demonstrated improved diagnostic performance for detecting Aβ+ compared to individual biomarkers, potentially reducing diagnostic uncertainty. These findings suggest that plasma biomarker ratios could be useful; however, further validation in independent and diverse clinical settings is necessary before broader clinical implementation.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lehmann, S., Gabelle, A., Duchiron, M., Busto, G., Morchikh, M., Delaby, C., et al. (2025). Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis. EBioMedicine. https://doi.org/10.1016/j.ebiom.2025.105805

Vancouver

Lehmann S, Gabelle A, Duchiron M, Busto G, Morchikh M, Delaby C, et al. Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis. EBioMedicine. 2025. doi:10.1016/j.ebiom.2025.105805. PMID: 40513421.

BibTeX

@article{lehmann2025-40513421,
  author  = {Lehmann, S. and Gabelle, A. and Duchiron, M. and Busto, G. and Morchikh, M. and Delaby, C. and Hirtz, C. and Mondesert, E. and others},
  title   = {{Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis}},
  journal = {EBioMedicine},
  year    = {2025},
  doi     = {10.1016/j.ebiom.2025.105805},
  pmid    = {40513421},
  url     = {https://doi.org/10.1016/j.ebiom.2025.105805}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

The pTau217/Aβ42 ratio demonstrated the highest diagnostic accuracy, with an AUC of 0.927 (0.900-0.954).
Interpretation The pTau217/Aβ42 ratio demonstrated improved diagnostic performance for detecting Aβ+ compared to individual biomarkers, potentially reducing diagnostic uncertainty.
These findings suggest that plasma biomarker ratios could be useful; however, further validation in independent and diverse clinical settings is necessary before broader clinical implementation.

Why it matters

A blood test measuring the ratio of two proteins, pTau217 and Aβ42, was better at detecting brain amyloid than measuring either protein alone. The authors say this ratio could be useful, but it needs to be validated in more and different clinical settings before it can be widely used.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants423
Evidence strengthModerate

How this study scored 59/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 57 of the 96 points we could judge it on, which is 59 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (EBioMedicine)
Journal's citation record	2 / 4	EBioMedicine: journal h-index 181 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	423 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	4 / 7	Cited 53 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	17.7 citations a year over 3 year(s) since 2025
Impact for its field and year	5 / 6	Cited 33.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 7 other studies in this library
Still being cited	3 / 4	Cited 53 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	2 / 3	Inserm: institution h-index 1,988 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 10 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40513421)
Free to read	2 / 2	Free to read
Points	57 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 57 of the 96 points we could judge it on is 59 out of 100.
Total	59 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.

Later studies that cite this one

7 studies in the alzhub library list this one in their references.

Related studies in Biomarkers

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →